Allogene Therapeutics Valuation
| ALLO Stock | USD 1.82 0.02 1.09% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Allogene Therapeutics shows a prevailing Real Value of $3.67 per share. The current price of the firm is $1.82. Our model approximates the value of Allogene Therapeutics from analyzing the firm fundamentals such as Shares Owned By Insiders of 17.42 %, current valuation of 175.17 M, and Return On Equity of -0.54 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Allogene Therapeutics' valuation include:
Price Book 0.8229 | Enterprise Value | Enterprise Value Ebitda (1.04) | Price Sales 8.9 K | Enterprise Value Revenue 4.1 K |
Undervalued
Today
Please note that Allogene Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Allogene Therapeutics is based on 3 months time horizon. Increasing Allogene Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Allogene Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Allogene Stock. However, Allogene Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.82 | Real 3.67 | Target 9.23 | Hype 1.78 |
The intrinsic value of Allogene Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Allogene Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Allogene Therapeutics helps investors to forecast how Allogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Allogene Therapeutics more accurately as focusing exclusively on Allogene Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Allogene Therapeutics' intrinsic value based on its ongoing forecasts of Allogene Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Allogene Therapeutics' closest peers.
Allogene Therapeutics Cash |
|
Allogene Valuation Trend
Knowing Allogene Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Allogene Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Allogene Therapeutics Total Value Analysis
Allogene Therapeutics is presently expected to have valuation of 175.17 M with market capitalization of 381.6 M, debt of 95.12 M, and cash on hands of 490.49 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Allogene Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
175.17 M | 381.6 M | 95.12 M | 490.49 M |
Allogene Therapeutics Investor Information
About 17.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.82. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 1.55. The entity had not issued any dividends in recent years. Based on the key indicators related to Allogene Therapeutics' liquidity, profitability, solvency, and operating efficiency, Allogene Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in February.Allogene Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Allogene Therapeutics has an asset utilization ratio of 0.0148 percent. This suggests that the Company is making $1.48E-4 for each dollar of assets. An increasing asset utilization means that Allogene Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Allogene Therapeutics Ownership Allocation
Allogene Therapeutics holds a total of 209.67 Million outstanding shares. The majority of Allogene Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Allogene Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Allogene Therapeutics. Please pay attention to any change in the institutional holdings of Allogene Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Allogene Therapeutics Profitability Analysis
The company reported the previous year's revenue of 95 K. Net Loss for the year was (327.26 M) with loss before overhead, payroll, taxes, and interest of (201.94 M).About Allogene Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Allogene Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Allogene Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Allogene Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Allogene Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Allogene Therapeutics. We calculate exposure to Allogene Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Allogene Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -218.5 M | -207.6 M | |
| Pretax Profit Margin | -4 K | -3.8 K | |
| Operating Profit Margin | -4 K | -3.8 K | |
| Net Loss | -4 K | -3.8 K | |
| Gross Profit Margin | -2.9 K | -2.8 K |
Allogene Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 156.9 M |
Allogene Therapeutics Current Valuation Indicators
Allogene Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Allogene Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Allogene Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Allogene Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Allogene Therapeutics' worth.When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.